AbbVie and Genmab reported positive Phase 3 results for Epkinly (elacestrant?) in combination with lenalidomide in diffuse large B-cell lymphoma, with the Epcore DLBCL-4 trial meeting its primary endpoint by reducing risk of progression or death by 60% versus R-GemOx, using FDA-relevant censoring rules. The companies did not provide overall survival in their release, but analysts said the result improves confidence ahead of the first-line Epcore DLBCL-2 readout.